European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management

Preschool Wheezing Phenotypes (<5 Years)

Wheezing affects approximately one in three children before their third birthday. In preschool children, confirm that the reported sound is wheeze, assess alternative diagnoses, and review symptom frequency and severity over time.

Clinical Patterns of Preschool Wheeze

Episodic viral wheeze and multiple-trigger wheeze are useful historical descriptions of symptom patterns. The ERS 2024 statement cautions that these labels alone do not identify airway pathology or predict treatment response:

---

Chronic Asthma Pathophysiology and Objective Assessment in School-Age Children (≥5 Years)

Childhood asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness, mucosal edema, Th2-mediated inflammation, and variable, reversible airflow obstruction.

Pathophysiological Cascade

In sensitized children, allergen exposure triggers dendritic cell presentation to naive T helper cells, inducing differentiation into Th2 lymphocytes. These cells release signature cytokines:

• Interleukin-4 (IL-4) and Interleukin-13 (IL-13): Drive B-cell immunoglobulin class switching to immunoglobulin E (IgE). IgE binds high-affinity FcεRI receptors on tissue mast cells and basophils.
• Interleukin-5 (IL-5): Promotes bone marrow maturation, migration, activation, and survival of eosinophils.
• Upon allergen cross-linking, mast cells degranulate, releasing histamine, cysteinyl leukotrienes (LTC4, LTD4, LTE4), and prostaglandin D2, causing immediate smooth muscle contraction, microvascular leakage, and thick mucus production.
• Ongoing inflammation induces airway structural remodeling, including subepithelial basement membrane thickening, smooth muscle hypertrophy, and goblet cell hyperplasia.

Objective Diagnostic Testing

BTS/SIGN and European guidelines emphasize that asthma is a clinical diagnosis supported by objective demonstrations of variable expiratory airflow limitation:

1. Spirometry: In children typically aged 5 to 7 years and older who can perform reproducible forced expirations:
   • Obstructive Pattern: Reduced forced expiratory volume in 1 second ($FEV_1$) relative to forced vital capacity ($FVC$), defined by an $FEV_1/FVC$ ratio below the lower limit of normal (typically <0.80 in children).
   • Bronchodilator Reversibility (BDR): An increase in $FEV_1$ of ≥12% (or ≥200 mL) after administering 400 mcg of inhaled salbutamol via spacer confirms significant, reversible airflow obstruction.
2. Fractional Exhaled Nitric Oxide (FeNO): Nitric oxide is synthesized by inducible nitric oxide synthase (iNOS) in respiratory epithelial cells in response to IL-4 and IL-13.
   • A FeNO concentration of ≥35 parts per billion (ppb) in symptomatic children supports the diagnosis of eosinophilic airway inflammation and predicts positive responsiveness to inhaled corticosteroids.

---

Stepwise Long-Term Pharmacological Management

Aim for normal activity, good symptom control and few exacerbations using the lowest effective treatment. Check diagnosis, adherence, inhaler technique and exposures before stepping up. The following is the BTS/NICE/SIGN pathway for ages 5–11; under-5 and adolescent pathways differ.

[Initial treatment: Low-dose ICS twice daily + SABA as needed]
                 |
                 v
[If uncontrolled: Can the child manage MART correctly?]
- Yes: Low-dose ICS-formoterol MART -> Moderate-dose MART if needed
- No: Trial LTRA for 8-12 weeks; stop if ineffective
      -> Low-dose ICS/LABA + SABA -> Moderate-dose ICS/LABA + SABA
                 |
                 v
[Uncontrolled on moderate-dose MART or ICS/LABA]
- Refer to a specialist in paediatric asthma
- Specialist reassessment before high-dose therapy or phenotype-specific biologics

Controller Selection and Review

• Initial Maintenance: Prescribe twice-daily low-dose ICS plus as-needed salbutamol. Dose bands depend on drug, device and guideline: GINA's examples for ages 6–11 include budesonide 100–200 mcg/day or fluticasone propionate 50–100 mcg/day. Check the selected product rather than assuming equal microgram potency. Established school-age asthma requires ICS-containing treatment; SABA alone does not treat inflammation.
• MART Pathway: If uncontrolled on low-dose ICS and able to manage the regimen, consider low-dose ICS-formoterol MART, increasing to moderate-dose MART if needed. The same inhaler provides maintenance and relief because formoterol acts rapidly; an ICS-salmeterol inhaler cannot serve this purpose. MART reduces exacerbations in appropriate children. Licensing varies: the UK November 2025 update identifies one budesonide-formoterol 100/6 mcg dry-powder product licensed for MART at 6–11 years; other products under 12 may be off-label. It is not universally approved from age 4.
• Conventional Pathway: If the child cannot manage MART, consider an 8–12-week LTRA trial with low-dose ICS and SABA; stop the LTRA if ineffective. If still uncontrolled, use a low-dose fixed ICS/LABA inhaler plus SABA, then moderate-dose ICS/LABA if necessary. An effective LTRA may be continued. Never prescribe LABA without ICS.
• Specialist Assessment: Refer if uncontrolled on moderate-dose MART or moderate-dose ICS/LABA, with or without an effective LTRA. Reassess diagnosis, technique, adherence and exposures before further escalation. Specialists may consider high-dose therapy, tiotropium or age- and phenotype-appropriate biologics such as omalizumab, mepolizumab or dupilumab. Review response after treatment changes and step down when sustained control permits.

Leukotriene Receptor Antagonists: Clinical Role and Neuropsychiatric Warnings

• Montelukast: An oral cysteinyl leukotriene receptor-1 antagonist, usually taken once each evening: 4 mg granules at 6 months–<2 years; 4 mg chewable or granules at 2–5 years; 5 mg at 6–14 years; 10 mg at ≥15 years. It may help selected persistent or exercise-related symptoms. Review an add-on trial after 8–12 weeks and stop if ineffective. Daily ICS is more effective for preschool maintenance, and LTRA does not reliably reduce viral-wheeze exacerbations needing oral steroids.
• Safety Advisory: European Medicines Agency (EMA) and UK MHRA black box alerts highlight the risk of neuropsychiatric adverse events. Prescribers must proactively warn parents regarding sleep disturbances, nightmares, aggression, irritability, depression, anxiety, and suicidal ideation. If neuropsychiatric symptoms occur, montelukast must be discontinued immediately.

---

Inhaler Delivery Systems, Spacer Mechanics, and Age-Appropriate Selection

Prescribing the correct inhaler device and verifying proper inhalation technique is as important as the choice of drug molecule. Poor inhalation technique is the leading cause of apparent treatment failure in pediatric asthma.

---

Emergency Stratification: Moderate, Severe, and Life-Threatening Asthma

When a child presents with an acute asthma exacerbation, immediate clinical categorization drives the escalation of acute resuscitation:

---

Acute Resuscitation Bundle for Pediatric Asthma

[Initial Assessment: Severe / Life-Threatening]
- High-Flow Oxygen via Reservoir Mask (Target SpO2 94-98%)
                 |
                 v
[First-Line Inhaled Bronchodilator Therapy]
- Salbutamol: 10 puffs via pMDI + spacer OR 2.5-5 mg oxygen-driven nebulizer
- Add: Ipratropium Bromide (250 mcg nebulized) every 20-30 min for the first hour
                 |
                 v
[Early Systemic Corticosteroids]
- Oral Prednisolone 1-2 mg/kg (max 40 mg) OR IV Hydrocortisone 4 mg/kg
                 |
                 v
[If Refractory to First-Hour Inhaled Therapy / Life-Threatening]
- IV Magnesium Sulfate: 40 mg/kg (max 2 g) IV infusion over 20 minutes
                 |
                 v
[PICU Escalation for Ongoing Deterioration]
- IV Salbutamol Infusion (1-5 mcg/kg/min) + Continuous ECG monitoring
- IV Aminophylline: 5 mg/kg loading; usual infusion 1 mg/kg/hr under 12, 0.5-0.7 mg/kg/hr at 12-17; follow local critical-care protocol
- Closely monitored non-invasive support when appropriate -> Experienced paediatric airway team if respiratory failure develops

1. Oxygen Delivery

Administer high-flow humidified oxygen via a tight-fitting non-rebreather reservoir face mask (10–15 L/min flow) to achieve and maintain target SpO2 between 94% and 98%.

2. Inhaled Short-Acting Beta-2 Agonist (Salbutamol)

• Moderate Exacerbation: Administer salbutamol 100 mcg via pMDI and spacer: 2 to 10 puffs, delivering 1 puff every 30 to 60 seconds with 5 tidal breaths per puff. Reassess after 20 to 30 minutes.
• Severe / Life-Threatening Exacerbation: Administer continuous or frequent salbutamol:
  • pMDI + Spacer: 10 puffs repeated every 20 to 30 minutes.
  • Nebulization: Driven by 6 L/min medical oxygen (never compressed air, to avoid worsening hypoxemia). Dose: 2.5 mg for children younger than 5 years; 5.0 mg for children aged 5 years and older. Can be given back-to-back every 20 minutes or as continuous nebulization (5–10 mg/hour).

3. Inhaled Anticholinergic (Ipratropium Bromide)

• Nebulized ipratropium bromide (250 micrograms) added to salbutamol every 20 to 30 minutes for the first hour of treatment in acute severe or life-threatening asthma.
• Blocks muscarinic M3 receptors, eliminating vagal bronchomotor tone and inhibiting mucus hypersecretion. The combination produces synergistic bronchodilation and significantly lowers hospital admission rates.

4. Early Systemic Corticosteroids

• Administer as early as possible within the first hour of presentation; clinical anti-inflammatory effects emerge within 2 to 4 hours.
• Oral Route (Preferred): Oral prednisolone 1 to 2 mg/kg (maximum 40 mg in preschool/school-age children; up to 50 mg in adolescents) once daily for 3 to 5 days. Routine tapering of steroids is completely unnecessary for courses under 7 days.
• Intravenous Route: Reserved for children unable to swallow, vomiting profusely, or in life-threatening exhaustion: IV hydrocortisone 4 mg/kg every 6 hours (maximum 100 mg per dose).

5. Second-Line Intravenous Therapies for Refractory Severe Asthma

If the child fails to improve after 1 hour of aggressive inhaled bronchodilators and systemic steroids, or exhibits immediate life-threatening features, initiate intravenous therapy without delay:

1. Intravenous Magnesium Sulfate:
   • Dosing: 40 mg/kg (maximum 2.0 grams) administered as an intravenous infusion in 100 mL of 0.9% normal saline over 20 minutes.
   • Mechanism: Potent physiological calcium channel blocker; inhibits calcium influx into bronchial smooth muscle cells, blocks acetylcholine release at motor nerve terminals, and suppresses histamine degranulation from mast cells.
   • Safety: Exceptionally safe; adverse effects are rare, including transient facial flushing, mild hypotension, and nausea. Monitor continuous heart rate and blood pressure.
2. Intravenous Salbutamol Infusion:
   • Dosing: IV bolus of 15 micrograms/kg (max 250 mcg) over 10 minutes, followed by a continuous infusion of 1 to 5 micrograms/kg/min (titrated to clinical response and heart rate).
   • Precautions: Monitor ECG, potassium, glucose and lactate. Beta-2 stimulation can cause tachycardia, intracellular potassium shifting and lactic acidosis, with compensatory tachypnea that can mimic worsening bronchospasm. Reassess perfusion, oxygenation and other causes such as hypovolemia or sepsis; do not automatically attribute a raised lactate to the drug. Review beta-agonist dosing if toxicity is suspected.
3. Intravenous Aminophylline:
   • Dosing: Load 5 mg/kg (max 500 mg) over 20–30 minutes; omit if already taking oral theophylline. A usual UK critical-care infusion is 1 mg/kg/hour below 12 years and 0.5–0.7 mg/kg/hour at 12–17 years, adjusted to response and concentrations under the local protocol.
   • Monitoring: This phosphodiesterase inhibitor has a narrow therapeutic index. Monitor ECG, electrolytes and clinical response. Follow the local theophylline-level protocol; many services check at 4–6 hours and then daily once stable (usual target 10–20 mg/L). Toxicity can cause serious arrhythmias and seizures.